<span item_type="fundamental" item_id="7cc6b9d5919fb1e3f93f764f5e9001b2" counter_id="ST/US/BFRI" env="prod"></span><span item_type="announcement" item_id="582319917376078721" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 6.988 M, missing the estimate of USD 7 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.62, missing the estimate of USD -0.58.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -6.532 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Total revenues for the third quarter of 2025 were $7.0 million, a decrease from $9.0 million in the third quarter of 2024, reflecting a 22% year-over-year decline due to advanced purchases ahead of the October 2024 price increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>Revenues for the first nine months of 2025 were stable at $24.6 million compared to $24.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Operating expenses decreased by 5% year-over-year in the third quarter of 2025 compared to the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>The net loss for the third quarter of 2025 was $6.6 million, compared to a net loss of $5.7 million for the prior-year quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>Adjusted EBITDA for the third quarter of 2025 was - $6.0 million compared to - $4.6 million for the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash balance was $3.4 million as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company completed the purchase of all Ameluz and RhodoLED US Assets from Biofrontera AG, reducing the payment rate to 12%–15% of U.S. net sales from 25%–35%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>The divestiture of Xepi antibiotic cream to Pelthos Pharmaceuticals was announced for $3 million at closing, $1 million upon commercial availability, and up to $6 million in milestone payments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Biofrontera Inc. anticipates substantial fourth quarter and year-over-year annual revenue growth, supported by growing demand for Ameluz-PDT treatment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>The company is encouraged by the potential of its clinical studies to gain FDA approval for the use of Ameluz to treat actinic keratoses on the entire body and potentially extend to superficial basal cell carcinoma and acne vulgaris.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>The acquisition of U.S. rights, approvals, and patents for Ameluz and RhodoLED lamps is expected to enhance gross margins and strengthen long-term profitability.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul>

Biofrontera | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 6.988 M